MARKET

NGEN

NGEN

Nervgen Pharma Corp
NASDAQ
1.960
+0.090
+4.81%
After Hours: 1.985 +0.025 +1.29% 19:40 06/29 EDT
OPEN
1.910
PREV CLOSE
1.870
HIGH
2.005
LOW
1.900
VOLUME
806.13K
TURNOVER
--
52 WEEK HIGH
6.30
52 WEEK LOW
1.700
MARKET CAP
208.16M
P/E (TTM)
-4.7887
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NGEN last week (0622-0626)?
Weekly Report · 17h ago
H.C. Wainwright Reaffirms Their Buy Rating on NervGen Pharma (NGEN)
TipRanks · 4d ago
Weekly Report: what happened at NGEN last week (0615-0619)?
Weekly Report · 06/22 09:06
Weekly Report: what happened at NGEN last week (0608-0612)?
Weekly Report · 06/15 09:06
NervGen rises as TD Cowen issues new Buy on lead asset
Seeking Alpha · 06/11 17:45
H.C. Wainwright Reaffirms Their Buy Rating on NervGen Pharma (NGEN)
TipRanks · 06/11 13:46
NERVGEN PHARMA CORP <NGEN.O>: TD COWEN INITIATES COVERAGE WITH BUY RATING
Reuters · 06/11 10:06
NervGen Pharma initiated with a Buy at TD Cowen
TipRanks · 06/11 09:51
More
About NGEN
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.

Webull offers NervGen Pharma Corp stock information, including NASDAQ: NGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NGEN stock methods without spending real money on the virtual paper trading platform.